Autoimmune hepatitis in children: What is different from adult AIH?

Seminars in Liver Disease

Volumn 29, Issue 3, 2009, Pages 297-306

  Mieli Vergani, Giorgina ^a   Vergani, Diego ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Autoimmune hepatitis; Children; Sclerosing cholangitis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVER KIDNEY MICROSOME TYPE 1 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; SMOOTH MUSCLE ANTIBODY; STEROID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ADULT; AUTOIMMUNE HEPATITIS; AUTOIMMUNE HEPATITIS TYPE 1; AUTOIMMUNE HEPATITIS TYPE 2; AUTOIMMUNE SCLEROSING CHOLANGITIS; BILE DUCT DISEASE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DIZZINESS; DRUG MEGADOSE; FAMILY HISTORY; HAIR LOSS; HEADACHE; HUMAN; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER INJURY; NAUSEA; NEUTROPENIA; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SCLEROSING CHOLANGITIS; SYMPTOM;

ADULT; AGE OF ONSET; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; CHILD; CHOLANGITIS, SCLEROSING; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; MALE; MUSCLE, SMOOTH; PREDICTIVE VALUE OF TESTS; RECURRENCE; TREATMENT OUTCOME;

EID: 68849121460     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1233529     Document Type: Review

References (55)

1. Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Textbook of Hepatology: From Basic Science to Clinical Practice. 3rd ed. Oxford, UK: Blackwell Publishing; 2007: 1089-1101
2. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25(3):541-547
3. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988;8(6):1662-1666
4. Ma Y, Okamoto M, Thomas MG, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35(3):658-664
5. Donaldson PT. Genetics in autoimmune hepatitis. Semin Liver Dis 2002;22(4):353-364
6. Ma Y, Bogdanos DP, Hussain MJ, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006;130(3):868-882
7. Fainboim L, Cañero Velasco MC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33(6): 1512-1517
8. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30(6): 1374-1380
9. Vergani D, Wells L, Larcher VF, et al. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis. Lancet 1985;2(8450):294-298
10. Liston A, Lesage S, Gray DH, Boyd RL, Goodnow CC. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. Immunol Rev 2005;204:87-101
11. Simmonds MJ, Gough SC. Genetic insights into disease mechanisms of autoimmunity. Br Med Bull 2004;71:93-113
12. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322(26):1829-1836
13. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18(4):998-1005
14. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5): 929-938
15. Hennes EM, Zeniya M, Czaja AJ, et al; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1): 169-176
16. Vergani D, Alvarez F, Bianchi FB, et al; International Autoimmune Hepatitis Group. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41(4):677-683
17. Gregorio GV, Bracken P, Mieli-Vergani G, Vergani D. Prevalence of antibodies to hepatitis C and herpes simplex virus type 1 is not increased in children with liver kidney microsomal type 1 autoimmune hepatitis. J Pediatr Gastroenterol Nutr 1996;23(5):534-537
18. Gregorio GV, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 1998;112(3):471-476
19. Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005;11(4):441-448
20. Cotler SJ, Kanji K, Keshavarzian A, Jensen DM, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis. J Clin Gastroenterol 2004; 38(9):801-804
21. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1(8528):292-294
22. Costa M, Rodríguez-Sánchez JL, Czaja AJ, Gelpí C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 2000;121(2):364-374
23. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355(9214):1510- 1515
24. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci 2007;52(9): 2433-2437
25. Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child 1992;67(12):1447-1453
26. Longhi MS, Mitry RR, Samyn M, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology 2009; February 18 (Epub ahead of print)
27. Longhi MS, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol 2004;41(1):31-37
28. Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4+CD25+regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun 2005; 25(1):63-71
29. Longhi MS, Hussain MJ,Mitry RR, et al. Functional study of CD4+CD25+regulatory T cells in health and autoimmune hepatitis. J Immunol 2006;176(7):4484-4491
30. Longhi MS, Meda F, Wang P, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology 2008;47(2): 581-591
31. Longhi MS, Hussain MJ, Bogdanos DP, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology 2007;46(2):472-484
32. Alvarez F. Autoimmune hepatitis and primary sclerosing cholangitis. Clin Liver Dis 2006;10(1):89-107, vi
33. Saadah OI, Smith AL, Hardikar W. Long-term outcome of autoimmune hepatitis in children. J Gastroenterol Hepatol 2001;16(11):1297-1302
34. Ferreira AR, Roquete ML, Toppa NH, de Castro LP, Fagundes ED, Penna FJ. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2008;46(1):65-70
35. Sogo T, Fujisawa T, Inui A, et al. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis. Hepatol Res 2006;34(3):187-192
36. Al-Chalabi T, Heneghan MA. Remission in autoimmune hepatitis: what is it, and can it ever be achieved? Am J Gastroenterol 2007;102(5):1013-1015
37. Kerkar N, Annunziato RA, Foley L, et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem. J Pediatr Gastroenterol Nutr 2006;43(5): 629-634
38. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41(1):207-215
39. Mieli-Vergani G, Bargiota K, Samyn M, Vergani D. Therapeutic aspects of autoimmune liver disease in children. In: Dienes HP, Leuschner U, Lohse AW, Manns MP, eds. Autoimmune Liver Diseases - Falk Symposium. Vol. 142. Dordrecht: Springer; 2005:278-282
40. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children. Clin Liver Dis 2002;6(3):623-634
41. Czaja AJ, Freese D; KAmerican Association for the Study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36(2):479-497
42. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35(4): 890-897
43. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354(1):54-66
44. Rumbo C, Emerick KM, Emre S, Shneider BL. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report. J Pediatr Gastroenterol Nutr 2002;35(3):391-398
45. Alvarez F, Ciocca M, Cañero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30(2):222-227
46. Cuarterolo M, Ciocca M, Velasco CC, et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine. J Pediatr Gastroenterol Nutr 2006;43(5): 635-639
47. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333(15):958-963
48. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up. J Hepatol 2009; April 9 (Epub ahead of print)
49. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35(8):515-519
50. Duclos-Vallée JC, Sebagh M, Rifai K, et al. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 2003;52(6):893-897
51. Kerkar N, Hadzić N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351(9100): 409-413
52. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33(3): 544-553
53. Underhill J, Ma Y, Bogdanos DP, Cheeseman P, Mieli-Vergani G, Vergani D. Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis. J Hepatol 2002;36 (Suppl 1):156A
54. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121(4):900-907
55. Scalori A, Heneghan MA, Hadzic N, Vergani D, Mieli-Vergani G. Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis: a 13-year follow up study. Hepatology 2007;46(Suppl): 555A